Tempest Therapeutics’ Promising Phase 3 Trial for Liver Cancer Treatment

Tempest Therapeutics, Inc. ((TPST)) announced an update on their ongoing clinical study.

Tempest Therapeutics, Inc. is conducting a Phase 3 clinical trial titled A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy. The study aims to evaluate whether the combination of TPST-1120 with atezolizumab and bevacizumab can extend patient survival compared to the standard treatment of atezolizumab and bevacizumab alone in patients with hepatocellular carcinoma (HCC) that cannot be surgically removed or has metastasized.

The intervention being tested includes TPST-1120, an orally administered drug that acts as a competitive antagonist of PPARα, combined with atezolizumab and bevacizumab, both administered intravenously. This combination is intended to improve patient outcomes by extending survival and controlling cancer progression.

The study design is interventional, randomized, and follows a parallel assignment model with quadruple masking (blinding of participants, care providers, investigators, and outcomes assessors). The primary purpose is treatment-focused, aiming to determine the efficacy and safety of the drug combination.

The study is not yet recruiting, with a start date set for November 4, 2024. The primary completion and estimated study completion dates have not been provided, but the last update was submitted on September 2, 2025. These dates are crucial for tracking the study’s progress and potential market entry.

The outcome of this study could significantly impact Tempest Therapeutics’ stock performance, as positive results may enhance investor confidence and position the company favorably against competitors in the oncology sector. The involvement of Hoffmann-La Roche as a collaborator further underscores the study’s potential industry impact.

The study is ongoing, with further details available on the ClinicalTrials portal.